Tianfeng Securities: Improvement in the market outlook for the innovative drug industry chain; focusing on the ramp-up of major products and related opportunities

A report from Tianfeng Securities believes that with the continued boom in domestic BD (business development) transactions, the innovation drug R&D boom is expected to continue. Tianfeng Securities believes that with innovation drug R&D demand staying intensely hot, domestic demand is likely to continue growing at a high rate, which could drive overall strong performance growth across the entire innovation drug industry chain. Focus on the scale-up and volume expansion of major single products and the corresponding opportunities. (People’s Finance Network)
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pinned